95 related articles for article (PubMed ID: 1802937)
1. Intrabacterial sodium-to-potassium ratios and ATP contents of Mycobacterium leprae from ofloxacin-treated patients.
Dietz M; Haas M; Lindner B; Dhople AM; Tebebe YB; Seydel U
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):548-57. PubMed ID: 1802937
[TBL] [Abstract][Full Text] [Related]
2. Determination of in vivo and in vitro drug effects of mycobacteria from the mass spectrometric analysis of single organisms.
Haas M; Lindner B; Dietz M; Tebebe YB; Seydel U
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):262-70. PubMed ID: 2071984
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy.
Grosset JH; Ji BH; Guelpa-Lauras CC; Perani EG; N'Deli LN
Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):281-95. PubMed ID: 2198315
[TBL] [Abstract][Full Text] [Related]
4. Assessment of viability by normal mouse foot-pad and bacillary ATP bioluminescence assay in multibacillary cases treated with an MDT regimen using conventional as well as newer drugs like minocycline and ofloxacin.
Gupta UD; Katoch K; Singh HB; Natrajan M; Sharma VD; Katoch VM
Indian J Lepr; 2000; 72(4):437-42. PubMed ID: 11212477
[TBL] [Abstract][Full Text] [Related]
5. Effect of treatment on PCR positivity in multibacillary leprosy patients treated with conventional and newer drugs ofloxacin and minocycline.
Singh HB; Katoch K; Natrajan M; Sharma RK; Gupta UD; Sharma VD; Singh D; Chauhan DS; Srivastava K; Katoch VM
Acta Leprol; 1999; 11(4):179-82. PubMed ID: 10987049
[TBL] [Abstract][Full Text] [Related]
6. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
[TBL] [Abstract][Full Text] [Related]
7. Ofloxacin containing combined drug regimens in the treatment of multibacillary leprosy.
Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
Southeast Asian J Trop Med Public Health; 1997 Dec; 28(4):803-10. PubMed ID: 9656405
[TBL] [Abstract][Full Text] [Related]
8. Ofloxacin for the treatment of leprosy.
Ji B; Grosset J
Acta Leprol; 1991; 7(4):321-6. PubMed ID: 1950440
[TBL] [Abstract][Full Text] [Related]
9. Persister studies in leprosy patients after multi-drug treatment.
Gupta UD; Katoch K; Singh HB; Natrajan M; Katoch VM
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):100-4. PubMed ID: 16830652
[TBL] [Abstract][Full Text] [Related]
10. Adenosine triphosphate content of Mycobacterium leprae from leprosy patients.
Dhople AM
Int J Lepr Other Mycobact Dis; 1984 Jun; 52(2):183-8. PubMed ID: 6373626
[TBL] [Abstract][Full Text] [Related]
11. Viability of Mycobacterium leprae in skin and peripheral nerves and persistence of nerve destruction in multibacillary patients after 2 years of multidrug therapy.
Job CK; Jayakumar J; Aschhoff M; Mathan MM
Int J Lepr Other Mycobact Dis; 1996 Mar; 64(1):44-50. PubMed ID: 8627112
[TBL] [Abstract][Full Text] [Related]
12. Activity of ofloxacin against Mycobacterium leprae in the mouse.
Grosset JH; Guelpa-Lauras CC; Perani EG; Beoletto C
Int J Lepr Other Mycobact Dis; 1988 Jun; 56(2):259-64. PubMed ID: 3045223
[TBL] [Abstract][Full Text] [Related]
13. Analysis of quantitative relationship between viability determination in leprosy by MFP, ATP bioluminescence and gene amplification assay.
Gupta UD; Katoch K; Sharma RK; Singh HB; Natragan M; Singh D; Sharma VD; Chauhan DS; Das R; Srivastava K; Katoch VM
Int J Lepr Other Mycobact Dis; 2001 Dec; 69(4):328-34. PubMed ID: 12035294
[TBL] [Abstract][Full Text] [Related]
14. A clinical trial of pefloxacin and ofloxacin in lepromatous leprosy.
Fajardo TT; Villahermosa LG; Cruz EC; Cellona RV; Balagon MV; Abalos RM; Gelber RH
Lepr Rev; 2004 Dec; 75(4):389-97. PubMed ID: 15685736
[TBL] [Abstract][Full Text] [Related]
15. Use of NASBA RNA amplification for detection of Mycobacterium leprae in skin biopsies from untreated and treated leprosy patients.
van der Vliet GM; Cho SN; Kampirapap K; van Leeuwen J; Schukkink RA; van Gemen B; Das PK; Faber WR; Walsh GP; Klatser PR
Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):396-403. PubMed ID: 9030105
[TBL] [Abstract][Full Text] [Related]
16. Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice.
Franzblau SG; Parrilla ML; Chan GP
Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):66-9. PubMed ID: 8392100
[TBL] [Abstract][Full Text] [Related]
17. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
[TBL] [Abstract][Full Text] [Related]
18. Viability determination of M.leprae: comparison of normal mouse foot pad and bacillary ATP bioluminescence assay.
Gupta UD; Katoch K; Natarajan M; Sharma VD; Sharma RK; Shivannavar CT; Katoch VM
Acta Leprol; 1997; 10(4):209-12. PubMed ID: 9447254
[TBL] [Abstract][Full Text] [Related]
19. Detection of viable organisms in leprosy patients treated with multidrug therapy.
Gupta UD; Katoch K; Singh HB; Natrajan M; Sharma VD; Katoch VM
Acta Leprol; 1999; 11(3):89-92. PubMed ID: 10544720
[TBL] [Abstract][Full Text] [Related]
20. Activity of two doses of rifampin against Mycobacterium leprae.
Husser JA; Traore I; Daumerie D
Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):359-64. PubMed ID: 7963907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
